Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

Metabolomic profiling: Blood samples will be collected from these subjects, and following metabolomic profiling, the data will provide the foundation for training machine learning models capable of recognizing the metabolomic profiles of subjects with endometrial carcinoma and differentiating them from subjects with other conditions.

Study summary

The study involves the use of reagents or materials for diagnostic assessments that are not commercially available, specifically a metabolomic signature for screening endometrial carcinoma and/or other types of cancers, and follows a case-control design.

This study aims to achieve several objectives that contribute to evaluating the diagnostic potential of a specific "metabolomic signature" to be used for screening endometrial carcinoma. Specifically, the study seeks to assess the signature's discriminative ability in differentiating between benign endometrial neoplasms and neoplasms of different histological origins.

Eligibility

Primary outcome measure(s)

• Creation and Testing of a Metabolomic Signature for Endometrial Carcinoma Screening — 24 months
• Evaluation of the Ability of the Metabolomic Signature to Discriminate Between Neoplasms of Different Histological Origins — 24 months
• Validation of the Developed Model in a Real-World Clinical Setting — 24 months

Trial sites (1)

More National Cancer Institute, Naples trials in Italy

Other trials for the same condition